- Policy
- What's the HIRA's solution to the drug price?
- by Lee, Hye-Kyung Dec 21, 2021 06:05am
- Measures have been prepared to improve administrative and economic losses caused by drug returns in hospitals, clinics, and pharmacies following the revision of the monthly drug benefit list and upper limit table. The HIRA has decided to provide a revision of the drug benefit list in advance starting this month. Until now, drug price files have
- Policy
- MFDS cancels all Jeil’s hypertension drugs for fabrication
- by Lee, Tak-Sun Dec 21, 2021 06:05am
- The Ministry of Food and Drug Safety issued a disposition revoking the sales licenses of all hypertension drugs manufactured by Jeil Pharmaceutical after the company was found to have submitted fabricated data for approval. A total of 44 items from 15 companies including Jeil Pharmaceutical were issued the disposition. The GMP investigati
- Company
- Is there a shortage of chickenpox vaccines?
- by Moon, sung-ho Dec 21, 2021 06:05am
- Contrary to the opinions of the medical community, SK Bio and GC Pharma said, "There is no problem in supplying chickenpox vaccines." The shortage of influenza (flu) vaccines in the second half of this year is causing confusion due to concerns that chickenpox vaccines may also be insufficient. Pharmaceutical and bio companies that produce chicke
- Company
- Losartan products are about to be withdrawn from the market
- by Kim, Jin-Gu Dec 20, 2021 06:12am
- With the recovery of Losartan with excessively detected impurities, pharmaceutical companies are considering strategies after recovery measures are completed. Many pharmaceutical companies that did not have a very high market share in the Losartan market are reportedly considering gradually withdrawing from the market after the recovery is co
- Opinion
- [Reporter’s View] Have we secured enough COVID-19 pills?
- by Dec 20, 2021 06:12am
- The world is in preparations to use oral COVID-19 treatments to end the pandemic. Following the UK, Demark became the second country to authorize the use of MSD’s (US Merck’s) ‘molnupiravir,’ with the EU and the US also reviewing approval of the said drug. Pfizer’s oral treatment ‘Paxlovid’ is also under regulatory review. Korea h
- Company
- EMA designated Hanmi's HM15211 as ODD
- by Kim, Jin-Gu Dec 20, 2021 06:12am
- Hanmi Pharmaceutical's LAPSTriple Agonist, HM15211 announced on the 17th that it has been designated as ODD by the European Medicines Agency (EMA). According to Hanmi Pharmaceutical, EMA recently designated it as ODD for the treatment of primary sclerosing cholangitis, PSC. The LAPSTriple Agonist has previously been designated as ODD by th
- Company
- Myung In’s Parkinson’s Tx demonstrates efficacy
- by Dec 20, 2021 06:12am
- A Parkinson’s disease treatment that Myung In Pharm has acquired an exclusive licensing agreement from an Israeli pharmaceutical company - 'P2B001 (Fixed-dose combination of pramipexole+rasagiline)’ &8211; has demonstrated its safety and efficacy at a global Phase III clinical trial. According to the topline results announced by the Is
- Company
- Expectations rise for Lilly’s Alzheimer drug
- by Eo, Yun-Ho Dec 20, 2021 06:11am
- Expectations have been rising for the commercialization of Lilly’s new drug candidate for Alzheimer’s. On the 15th (local time), Eli Lilly announced that it will complete filing for approval of its new Alzheimer’s candidate ‘donanemab’ within the first quarter of 2022. The news was announced at an investor meeting while introducin
- Policy
- Korea tightens social distancing measures again
- by Kim, Jung-Ju Dec 20, 2021 06:11am
- The surge in COVID-19 cases in Korea has led the government to once again tighten the reins on social distancing while focusing on encouraging booster shot vaccinations. Private gatherings will be once again limited to no more than four people in all areas regardless of region, and a ‘vaccine pass’ that differs the level of restrictions
- Company
- Ildong signed for Nexium worth ₩50 billion
- by Dec 20, 2021 06:11am
- AstraZeneca Korea announced on the 14th that it has signed a partnership contract with Ildong for gastroesophageal reflux disease treatment "Nexium (Esomeprazole)" and type 2 diabetes treatment "Qtern (Dapagliflozin/Saxagliptin Monohydrate)." Through this, Ildong Pharmaceutical will jointly sell Nexium and Qtern with AstraZeneca Korea from
